

October 1, 2024  
 Web Announcement 3453

## Updates to Coverage and Reimbursement of COVID-19 Products

With the mandatory coverage of COVID-19 products ending on the last day of the first calendar quarter that begins one year after the last day of COVID-19 Public Health Emergency (PHE), Nevada Medicaid pharmacy program has implemented the following changes to its COVID-19 coverage and reimbursement policies, effective October 1, 2024:

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Emergency Use Authorization (EUA) COVID-19 Products & Vaccines	<p>Coverage for Emergency Use Authorized (EUA) COVID-19 products (i.e., Lagevrio) will no longer be provided.</p> <p>COVID-19 vaccines approved for administration will be covered according to the recommendations of the Advisory Committee on Immunization Practices (ACIP). Coverage for COVID-19 vaccines for recipients 19 years of age and under is provided through the Vaccine for Children’s (VFC) program. Medicaid recipients under 19 years of age receiving a non-VFC-provided COVID-19 vaccine, that is approved for administration, may receive coverage through the prior authorization process.</p>
Vaccine Administration Fee	<p>The enhanced administration fee for COVID-19 vaccines will revert to the standard rate of \$7.80 for pharmacist-administered vaccinations</p>
At-home COVID-19 Tests	<p>The current standing order for at-home, over-the-counter (OTC) COVID-19 tests dated March 9, 2022, will be terminated. Coverage will be limited to two (2) tests per 30 days at a Maximum Allowable Cost (MAC) rate of \$6.85 per test</p>